Pharma Sources Insight August 2021: From the Editor

Pharma Sources Insight August 2021 

Dear Readers,

No one knows what the future will be like while COVID-19 keep challenging the world health. Well, the endpoint is what Pharma is endeavor to achieve. 

Scenario of the pharma industry in H1 of 2021:

Vaccine and Vaccination: Up to July 2021, 17 COVID-19 vaccines which have been marketed worldwide; a number of 336940 million doses of COVID-19 vaccines have been administered worldwide, around 926 million people are fully dosed, covering about 611.9% of the world's population in bout 170 countries and regions, of which Israel, China, India and United States enjoy a leading vaccination coverage globally. 

M&A: While pharma and medtech R&D has been profoundly disrupted since the pandemic, in the first 6 months of 2021, the pharmaceutical and life sciences (PLS) sector has seen robust volume return to reach $123.3 Billion, with M&A activities related to innovation and maximization the potential of portfolios of the companies continues, based on PWC’s analyst.

Lisence In/Out: In China, On June 30, Allist announced that it intends to enter into an agreement with ArriVent Biopharma to authorize the latter the right to exclusively develop Furmonertinib outside Greater China. Earlier before, another two third-generation EGFR-TKIs have been authorized to be marketed outside China, which are Avitinib and Almonertinib. And more drugs have been subject to overseas authorization in the first half of 2021.

Pharma Trade: In the first half of 2021, a solid global demand in response to lockdowns and vaccinations has quicken the export growth of China. According to the data provided by Trading Economics and Daxue Consulting, China's exports of Pharmaceutical Products increased to $4853258 thousand in May of 2021, reaching an all time high since its record low of 77631 USD THO in January of 1996, and the volume is forecasted to rise to $10.2 billion by 2023.

Meanwhile, new drugs are finding its way to shaping the industry:

• On June 07, 2021, the US FDA approved Biogen’s aducanumab (Aduhelm) for the treatment of AD, which makes it the first therapy to target the underlying disease process. 

• It is expected that a new kind of vaccine, inhaled COVID-19 vaccine will be a more user-friendly and cost-effective way to get vaccinated quickly. 

Also, there are some updates from PharmaSources.com too, with a new feature to be launched soon, followers of Pharma Sources Insight will be able to browse all the previous issues in just one page, even more, you will be able to separately download each issue to secure the reading without internet. So if you are looking for medical supplies manufacturers, Pharmasources would be your best choice.

In this issue, thank you for the strong support from the PharmaSources.com supplier: Nanjing Foreign Economic & Trade Development Co., Ltd. Thanks for all our contributors. We will keep striving for providing quality pharma content and helping build connections in the pharma society, thank you for keeping staying with us.

Pharma Sources Insight

References:

1. https://tradingeconomics.com/china/exports-of-pharmaceutical-products

2. https://daxueconsulting.com/pharmaceutical-industry-china/#:~:text=China's%20dynamic%20pharmaceutical%20trade%20environment&text=In%202018%2C%20China's%20pharmaceutical%20imports,to%20%2410.2%20billion%20by%202023.

3. https://www.reuters.com/world/china/chinas-june-exports-growth-beats-fcast-easing-global-lockdowns-boost-demand-2021-07-13/

4. https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-insights.html